Brilliant presentation.
Unfortunately I had something on whilst it was being broadcast so could only read it after although the message couldn't have been more clear....
We are onto a Winner.
Slide 71 very interesting,
"Anteris TAVR studies will potentially qualify as a Category B study."
"Anteris will commence supplying product during its FDA studies at approx USD25k per unit."
"First TAVR revenues will commence in 2023."
Also, brilliant update in presentation and confirmed in separate announcement subsequently.... the study in Georgia has started to treat its second cohort of patients.
Brilliant presentation.Unfortunately I had something on whilst...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.05 |
Change
-0.140(2.70%) |
Mkt cap ! $78.29M | |||
| Open | High | Low | Value | Volume |
| $5.08 | $5.17 | $5.00 | $17.07K | 3.383K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 27 | $5.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.18 | 2446 | 1 |
View Market Depth
| Last trade - 15.59pm 30/07/2025 (20 minute delay) ? |
| AVR (ASX) Chart |